Topic: Bayer AG
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced that more than 70 studies evaluating the use of Nexavar? (sorafenib) tablets will be presented at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4-8, 2010, in Chicago, IL.. ...
Another weak quarter for kidney and liver cancer treatment Nexavar prompted a 5% drop in Onyx Pharmaceuticals' (ONXX) shares Thursday and questions about what exactly is driving the disappointing figures.. Just how concerned followers of the US biotech should be remains to ...
Onyx Pharmaceuticals Changing the Way Cancer is Treated Press Releases Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress. Nexavar's Differentiated Mechanism Nexavar targets both the ...
LONDON (Reuters) - Britain's healthcare cost-effectiveness watchdog has again rejected Bayer's drug Nexavar for treating liver cancer on the state health service, despite a revised charging scheme from the company.Wednesday's decision is a setback for Bayer and its partner Onyx Pharmaceuticals, which ...
ONXX) today announced that more than 65 studies evaluating the use of Nexavar(R) (sorafenib) tablets will be presented at the 2009 American Society of Clinical Oncology (ASCO) annual meeting. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. In RCC ...
NEW YORK (Reuters) - Onyx Pharmaceuticals Inc < said on Sunday it sued Bayer AG < over its rights to an anti-cancer compound that it says it discovered during joint research with the German drugmaker.Onyx's lawsuit, filed in the U.S. District Court ...
Patients with advanced portal hypertension may benefit from sorafenib, researchers report in the April issue of Hepatology.. Marc Mejias, of Hospital Clinic, Ciberehd in Barcelona, Spain, and colleagues studied the effects of sorafenib in two animal models: They also observed significant improvements ...
Subanalyses from the Phase 3 SHARP and Asia-Pacific trials to be presented at 59th Annual Meeting of the American Association for the Study of Liver Diseases -. Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced that new Nexavar data will ...
said it won approval from Chinese regulators for the use of its cancer pill Nexavar, which it is jointly developing with Onyx Pharmaceuticals (nasdaq: The clearance makes Nexavar, based on the active ingredient sorafenib, the first liver cancer therapy available in China ...
Nexavar is First Approved Systemic Therapy to Treat the Disease - Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that The New England Journal of Medicine published results of a Phase 3 trial demonstrating that Nexavar(R) (sorafenib) tablets decreased the absolute ...
Photo Gallery
-
Tougher Jobs
In this photo taken on Wednesday, Oct. 6, 2010, Joe Bozada, chief-of-staff ...AP News - -
Swine Flu Shots Businesses
In this photo made on Friday, Sept. 11, 2009, Hubert Moore, an ...AP News - -
Unproven Remedies Business
FILE - In this Nov. 27, 2006 file photo, the logo of German ...AP News -
